Metoclopramide

Metoclopramide is both an antiemetic, a drug that controls nausea and vomiting, and a prokinetic, one that speeds the passage of contents through the upper gut ^[1][3]. Chemically it is a substituted benzamide, related to compounds such as cisapride, and its principal pharmacological action is the blockade of dopamine D2 receptors ^[1][3]. It is well absorbed by mouth and is also given by injection ^[1].

The drug was first described in 1964 by Louis Justin-Besancon and Charles Laville, who came upon it while trying to improve the properties of the antiarrhythmic procainamide ^[1]. It reached the market in Europe that same year as Primperan, and it was later introduced in the United States as Reglan, first as an injection and then in oral form, with generic versions following in the 1980s ^[1]. It is also sold as Maxolon and under many other names worldwide ^[1].

Metoclopramide is used to prevent and treat nausea and vomiting from causes such as chemotherapy, radiation, surgery, and migraine, to accelerate stomach emptying in gastroparesis, and to relieve gastroesophageal reflux ^[1][3]. It is sometimes combined with pain relievers in the treatment of migraine and is used to speed the gut during certain radiological procedures ^[1]. In pregnancy it has been a commonly chosen antiemetic, and large cohort studies have found no increased risk of birth defects or other adverse outcomes when it is used in the first trimester ^[1][4]. Because prolonged use raises the risk of a movement disorder, guidelines generally advise keeping courses short ^[1][2].

Metoclopramide is a prescription medicine on the World Health Organization's Model List of Essential Medicines, available as tablets, oral liquid, and injectable solution ^[1]. Its most important side effects arise from its blockade of dopamine in the brain and include restlessness (akathisia), muscle spasms, and, with long-term use, tardive dyskinesia, a potentially lasting movement disorder ^[1][2]. In 2009 the United States Food and Drug Administration added a boxed warning about this risk, and regulators advise against continuous use beyond about twelve weeks ^[1][2]. Other effects include drowsiness and diarrhea, and the drug is avoided in conditions such as Parkinson's disease and bowel obstruction ^[1].

Metoclopramide is prescription and carries a boxed warning for tardive dyskinesia, a potentially irreversible movement disorder of the face and limbs whose risk climbs with dose and duration, so use is generally limited to 12 weeks. Other movement effects include acute muscle spasms (dystonia), restlessness (akathisia), and Parkinson-like symptoms, and rarely the dangerous neuroleptic malignant syndrome. It can also raise prolactin, causing breast tenderness or milk production, and prolong the QT interval. It should be avoided in Parkinson's disease, bowel obstruction or perforation, and pheochromocytoma, and doses are cut in kidney impairment.

Metoclopramide is a dopamine receptor antagonist that can worsen Parkinson's disease symptoms through pharmacodynamic antagonism at dopamine receptors in the central nervous system. Co-administration with carbidopa/levodopa reduces the symptomatic benefit of levodopa and may exacerbate motor symptoms.

Metoclopramide carries a documented risk of tardive dyskinesia (involuntary repetitive movements); a real-world study found tardive dyskinesia incidence of 0.37% per person-year in metoclopramide-treated gastroparesis patients ^[6]. Risk factors include prolonged use, older age (particularly 65 years and above), female sex, concurrent dopamine antagonists, and pre-existing neurological conditions like Parkinson's disease. Metoclopramide has not been systematically studied for interactions with most other common medications.

Checking a whole stack? Run it through interactions + stacks.

Metoclopramide was developed in France in the early 1960s by researchers at Laboratoires Delagrange, where chemists working on derivatives of the local anesthetic and antiarrhythmic procainamide produced a substituted benzamide that unexpectedly combined antinausea and gut-stimulating properties. It entered clinical use in the 1960s and quickly established itself as a dual-purpose agent, both calming nausea through central dopamine blockade and accelerating the movement of the upper digestive tract.

Over the following decades it became a mainstay for chemotherapy-induced and postoperative nausea, gastroparesis, and reflux, and it is sold under brand names including Reglan and Maxolon. Recognition of its movement-related side effects, particularly the risk of tardive dyskinesia with prolonged exposure, led regulators to recommend short treatment courses and, in some regions, a boxed warning. It nonetheless remains sufficiently valued to appear on the World Health Organization's list of essential medicines.

Metoclopramide has endured for more than half a century because it does two useful things at once, relieving nausea while actively coaxing a sluggish stomach to empty, a combination that few other single drugs offer. For decades it was essentially the only agent approved in the United States for diabetic gastroparesis, and it remains a go-to option for nausea in settings ranging from migraine attacks to the recovery room.

Clinicians appreciate its rapid onset and its availability in oral, intravenous, and even nasal-spray forms, and it is inexpensive and globally available. Candor is important here: because it readily enters the brain, the same central dopamine blockade that stops nausea can, especially with extended use, produce movement disorders, which is why courses are deliberately kept short and doses conservative. Used with that respect for its limits, metoclopramide continues to be a genuinely useful and well-understood tool for nausea and impaired gastric motility.